Pfitzer Torsten, Niederhoffer Nathalie, Szabo Bela
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albert-Ludwigs-Universität, Albertstrasse 25, 79104 Freiburg i. Br., Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2005 Jan;371(1):9-17. doi: 10.1007/s00210-004-1003-9. Epub 2005 Jan 20.
Activation of CB(1) cannabinoid receptors by exogenous agonists causes presynaptic inhibition of neurotransmitter release from axon terminals. In the central nervous system, presynaptic CB(1) receptors can also be activated by endogenous cannabinoids (endocannabinoids) released from postsynaptic neurons. Except in the vas deferens, there is no indication of endocannabinoid-mediated presynaptic inhibition in the sympathetic nervous system. The aim of the present study was to search for such inhibition in pithed rats. Artificial sympathetic tone was established by continuous electrical stimulation of preganglionic sympathetic axons. The CB(1) cannabinoid receptor antagonist rimonabant (0.5 and 2 mg kg(-1) i.v.) did not change blood pressure, heart rate or plasma noradrenaline concentration. Since activation of Galpha(q/11) protein-coupled receptors enhances endocannabinoid synthesis in the central nervous system, we attempted to stimulate endocannabinoid production by infusion of arginine vasopressin and phenylephrine (both activate Galpha(q/11) protein-coupled receptors). Rimonabant (2 mg kg(-1) i.v.) did not change blood pressure, heart rate or plasma noradrenaline concentration during infusion of phenylephrine or vasopressin. In the final series of experiments we verified that an exogenous cannabinoid agonist produces sympathoinhibition. The synthetic CB(1)/CB(2) receptor agonist WIN55212-2 (0.1 and 1 mg kg(-1) i.v.) markedly lowered blood pressure and plasma noradrenaline concentration in pithed rats with electrically stimulated sympathetic outflow. In contrast, in pithed rats with a pressor infusion of noradrenaline, WIN55212-2 did not change blood pressure or heart rate. The results verify that activation of peripheral presynaptic CB(1) receptors inhibits noradrenaline release from sympathetic nerve terminals. The lack of effect of the CB(1) receptor antagonist rimonabant indicates that, even under conditions favouring endocannabinoid synthesis, endocannabinoid-mediated presynaptic inhibition is not operating in the sympathetic nervous system of the pithed rat.
外源性激动剂激活CB(1)大麻素受体可引起轴突终末神经递质释放的突触前抑制。在中枢神经系统中,突触前CB(1)受体也可被突触后神经元释放的内源性大麻素(内源性大麻素)激活。除了在输精管中,没有迹象表明交感神经系统中存在内源性大麻素介导的突触前抑制。本研究的目的是在去大脑大鼠中寻找这种抑制作用。通过持续电刺激节前交感神经轴突建立人工交感神经张力。CB(1)大麻素受体拮抗剂利莫那班(0.5和2 mg kg(-1)静脉注射)并未改变血压、心率或血浆去甲肾上腺素浓度。由于Gα(q/11)蛋白偶联受体的激活可增强中枢神经系统内源性大麻素的合成,我们试图通过输注精氨酸加压素和去氧肾上腺素(两者均激活Gα(q/11)蛋白偶联受体)来刺激内源性大麻素的产生。在输注去氧肾上腺素或加压素期间,利莫那班(2 mg kg(-1)静脉注射)并未改变血压、心率或血浆去甲肾上腺素浓度。在最后一系列实验中,我们证实外源性大麻素激动剂可产生交感神经抑制作用。合成的CB(1)/CB(2)受体激动剂WIN55212-2(0.1和1 mg kg(-1)静脉注射)可显著降低电刺激交感神经传出的去大脑大鼠的血压和血浆去甲肾上腺素浓度。相比之下,在输注去甲肾上腺素进行升压的去大脑大鼠中,WIN55212-2并未改变血压或心率。结果证实外周突触前CB(1)受体的激活可抑制交感神经终末去甲肾上腺素的释放。CB(1)受体拮抗剂利莫那班缺乏作用表明,即使在有利于内源性大麻素合成的条件下,内源性大麻素介导的突触前抑制在去大脑大鼠的交感神经系统中也不起作用。